ClinicalTrials.gov
public full text
Public Domain
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
The purpose of this study is to evaluate the efficacy and safety of febuxostat 40 mg extended release (XR) and 80 mg XR in comparison with febuxostat 40 mg immediate release (IR) and 80 mg IR, respectively, in participants with gout.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Phase III Trial of Febuxostat in Korea Gout Patients#1138254
- [Association of metabolic syndrome and its components with gout: an analysis based on a large-scale health survey database].#165895
- New Application of Buprenorphine Patch on Painful Knee Joint in Knee Osteoarthritis Patients#836021
- Cryo and Compression Therapy After TKA and UKA#1057220
- Postoperative Pain and Analgesic Requirements After Preoperative Methadone for Primary TKA#831231
Record · ID 1153502
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive